Invited reviewRecent developments in the field of antitumour anthracyclines
Section snippets
Acknowledgements
I am indebted to Dr. J. Robert for information on the topic and to Dr. J.-P. Buisson for critical reading of the manuscript.
References (127)
Biochem. Pharmacol.
(1999)- et al.
Eur. J. Cancer Clin. Oncol.
(1985) - et al.
Eur. J. Cancer
(1990) - et al.
Tetrahedron Lett.
(1968) - et al.
Pharmacol. Ther.
(1993) Biochimie
(1998)- et al.
Pharmacol. Ther.
(1997) - et al.
Clin. Oncol.
(1993) - et al.
Ann. Oncol.
(1998) - et al.
Biochim. Biophys. Acta
(2000)
Eur. J. Cancer
(1998)
Eur. J. Cancer
(1999)
Bioorg. Med. Chem. Lett.
(1998)
Bioorg. Med. Chem. Lett.
(1998)
Bioorg. Med. Chem. Lett.
(2000)
J. Controlled Release
(1992)
Adv. Drug Deliv. Rev.
(1997)
Doxorubicin, Anticancer Antibiotics
(1981)
Science
(1984)
Cancer
(1985)
Cancer Treat. Rep.
(1978)
Biotechnol. Bioeng.
(1969)
Curr. Med. Chem.
(1998)
Curr. Pharm. Des.
(1999)
J. Antibiot.
(1977)
J. Antibiot.
(1975)
C. R. Acad. Sci. Ser. D
(1972)
Cancer Treat. Rep.
(1976)
Drugs
(1997)
Cancer Res.
(1988)
J. Antibiot.
(1979)
Cancer Res.
(1975)
J. Org. Chem.
(1979)
Gan To Kagaku Ryoho
(1997)
Gan To Kagaku Ryoho
(1997)
Invest. New Drugs
(1993)
Invest. New Drugs
(1993)
J. Neurooncol.
(1992)
Biochemistry
(1997)
J. Antibiot.
(1988)
Cancer Chemother. Pharmacol.
(1999)
Invest. New Drugs
(1996)
Anticancer Drug Des.
(1995)
Cancer Res.
(2001)
Cancer Res.
(2001)
Oncol. Res.
(1998)
Proc. Am. Soc. Clin. Oncol.
(1997)
Cited by (148)
Design, synthesis and biological evaluation of rhein-piperazine-dithiocarbamate hybrids as potential anticancer agents
2022, European Journal of Medicinal ChemistrySpectroscopic, quantum chemical and molecular docking studies on 1-amino-5-chloroanthraquinone: A targeted drug therapy for thyroid cancer
2021, Spectrochimica Acta - Part A: Molecular and Biomolecular SpectroscopyGreen preparation of carbon dots from plum as a ratiometric fluorescent probe for detection of doxorubicin
2021, Optical MaterialsCitation Excerpt :It can kill cancer cells by inhibiting the synthesis of RNA and DNA in the cancer cell cycle [1,2]. On the other hand, DOX has some side-effects of causing bone marrow suppression and cardiotoxicity [3]. In clinic, monitoring the concentration of DOX in human biofluids can guide its reasonable clinical dosage, thereby ensuring the effectiveness of treatment and minimizing the toxicity to patients.
Copyright © 2001 Éditions scientifiques et médicales Elsevier SAS. All rights reserved.